Creative Biolabs Enhances IVD Services with Integrated Protein and Nucleic Acid Detection
TL;DR
Creative Biolabs' advanced protein and nucleic acid detection services provide researchers with faster, more accurate disease identification for competitive advantage in diagnostics and drug development.
Creative Biolabs utilizes ELISA, mass spectrometry, and multiplex assays in systematic protein biomarker detection processes that deliver reliable, reproducible data from limited sample volumes.
These advanced diagnostic technologies enable earlier disease detection, improving patient outcomes and making healthcare more proactive and effective for a better tomorrow.
Creative Biolabs combines protein and nucleic acid detection in single assays, revealing cross-level molecular interactions that could revolutionize early disease diagnosis.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs has significantly expanded its in vitro diagnostic (IVD) capabilities through the integration of protein and nucleic acid detection services, marking a substantial advancement in molecular diagnostics and precision medicine. The company now offers systematic protein-level detection services that enable researchers to obtain reliable data even from limited sample volumes, leveraging proteins as direct mediators of physiological and pathological processes.
According to a Creative Biolabs expert, protein level studies track disease onset and development more rapidly than genetic testing alone. The company's high-sensitivity technology platforms ensure stable and reproducible results, which is crucial for disease diagnostics and drug development. The expanded services include comprehensive protein biomarker detection services utilizing ELISA, multiplex assays, mass spectrometry, and protein arrays for quantitative target detection and large-scale proteomics.
Creative Biolabs has also developed innovative combined nucleic acid and protein detection services that analyze both protein and nucleic acid signals simultaneously in a single assay. This integrated approach conserves sample volume and time while revealing cross-level molecular interactions, enhancing the rationale for early disease detection and clinical assessment. The combined detection method has demonstrated advantages in studies on complex conditions such as pancreatic cancer and cardiovascular disease.
The expansion of these services addresses the growing prominence of protein- and nucleic acid-based biomarkers, particularly for early disease detection. By rigorously controlling every step from sample preparation to data interpretation, Creative Biolabs ensures the delivery of reliable, high-quality data that meets the stringent standards of researchers. This advancement in IVD capabilities supports more accurate identification of disease patterns and could shape the future of diagnostic technologies, benefiting research in cancer, neurodegenerative diseases, and infectious diseases worldwide.
Curated from 24-7 Press Release
